[Analysis of the Effect of TET2 Mutation and SNP on Clinical Characteristics and Prognosis of AML Patients]

Objective: To evaluate the clinical significance of TET2 mutation(TET2^mut) and SNP in adult acute myeloid leukemia (AML) and its effect on prognosis.

Methods: A total of 24 genes, including TET2, FLT3-ITD and NPM1, were detected in 124 adult AML patients using second-generation sequencing technology, and their clinical characteristics and effect on prognosis of patients were analyzed.

Results: A total of 25 TET2 gene mutations were detected in 124 AML patients, the mutation rate was 20.2%, there were 75 cases of TET2 single nucleotide polymorphisms(SNP), accounting for 60.5%. There were 47 cases of SNPrs2454206(G>A), accounting for 37.9%. Compared with TET2 wild-type(TET2^wt) patients, TET2^mut patients were mostly elderly. TET2SNP was commonly seen in male, with statistically significant differences (P＜0.05). SNP rs2454206 had no significant correlation with sex and age (P＞0.05). However, the analysis found that the complete remission rate of 1 course and the total complete rate (CR) of patients with TET2^AG/GG were both obviously superior to those with TET2^AA (P＜0.05). In the univariate analysis, the overall survival(OS) rate of the patients with TET2^mut was lower than that of patients with TET2^wt, and the event free survival (EFS) rate was higher than that of TET2^wt patients, but the difference was not statistically significant (P＞0.05).The 1-year OS rate and EFS rate of the patients with TET2^AA were significantly lower than those of the patients with TET2^AG/GG (P＜0.05). Multivariate analysis showed that TET2^AA was an independent risk factor for OS and EFS in AML patients.

Conclusion: TET2 SNPrs2454206(G＞A) commonly appears in patients with acute myeloid leukemia, and these patients have the better response to chemotherapy and a better prognosis.